Theranostics Australia


Private Theranostics Provider in Australia

We strive to develop and provide powerful innovative therapies

Established in May 2015, we are dedicated to continuously developing and utilising targeted molecular diagnostic imaging and therapeutic agents for the diagnosis and treatment of cancers. We have a particular focus on cancers which are difficult to treat or are becoming resistant to conventional therapies. Contact us today to find out more.

Our knowledge of how to treat cancer is the culmination of years of research, education and application of the most innovative developments in the field. Our team of specialists, supported by advanced technologies at our facilities, works tirelessly to offer the most innovative cancer treatments on the market.

For more information, select a cancer type to be directed to a therapy offered by Theranostics Australia.

For modern cancer treatment and a team of specialists who care about your wellbeing, contact us today.

Lutetium-177 Octreotate therapy

Lutetium-177 Octreotate therapy is used to treat neuroendocrine tumours (NETs) that emerge from the endocrine or nervous system such as carcinoid tumours. It aims to reduce the size of the tumour(s) and stop them from multiplying, as well as to ease the associated symptoms. Read More

Lutetium-177 PSMA therapy

Lutetium-177 PSMA therapy is used for people with advanced prostate cancer. It is most often used when the disease has metastasised, and when other therapies are poorly tolerated or have failed. In certain patients, it can produce long-term remission. Read More

Radium-223 therapy

Radium-223 therapy is used for people who have prostate cancer that has spread to the bones. The therapy damages the cancer cells in the bone, leading to the tumours shrinking in size, or even disappearing altogether. It is also used to reduce pain that can be associated with bone cancer. Read More

Iodine-131 therapy

Iodine-131 therapy is a thyroid cancer treatment that uses radiation to treat either thyroid cancer or a hyperactive thyroid (thyrotoxicosis) by targeting the thyroid tissue. Read More

Yttrium-90 SIRT therapy

Yttrium-90 SIRT Therapy, or Selective Internal Radiation Therapy, is a treatment for cancers and tumours located within the liver. The aim of this treatment is to reduce the size of inoperable tumours or decrease the number of lesions in the liver. It may allow for the surgical removal of tumours, once considered inoperable. It may also stabilise the disease and prolong the life of the patient. Read More

Yttrium-90 Radiosynovectomy therapy

Yttrium-90 Radiosynovectomy therapy is a treatment for painful joints caused by arthritis or other types of joint diseases, often providing relief for sufferers. Read More

Theranostics Australia has collaborative ties to


Review of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate CancerLenzo N , Meyrick D and Turner J.Diagnostics2018 February
The role of 68Ga-PSMA-I&T PET/CT in the pretreatment staging of primary prostate cancerMeyrick D, Asokendaran M, Skelly LA, Lenzo NP, Henderson A.Nuclear Medicine Communications2017 November

View More

European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) on “Lutathera”

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended eleven medicines for approval at its July 2017 meeting. This included Lutathera (lutetium [177Lu] oxodotreotide), an orphan drug for the treatment of well differentiated gastro-entero-pancreatic neuroendocrine tumours. (1/2) Read More >>

Lutetium-177 OPS-201 Trial for Treatment of Progressive Metastatic Neuroendocrine Tumours (NETs)

The OPS-201 trial has now commenced in Perth. This IPSEN sponsored trial involves the use of Lutetium-177 OPS-201 for treatment of progressive metastatic neuroendocrine tumours (NETs). Theranostics Australia is one of several sites worldwide currently recruiting (together with Peter Mac in Melbourne, Royal Free in London and Memorial Sloan Kettering in New York).

This agent binds to both activated and unactivated somatostatin receptors which are upregulated on these tumours. There is far higher binding via this mechanism than standard octreotate.

The protocol involves 3 cycles 8 weeks apart of intravenous Lu-177 OPS-201. All patients will have baseline Ga-68 octreotate imaging performed.

The treatment is available for all NET patients with progressive metastatic disease including gastric and pancreatic NETs, pulmonary carcinoids, paraganglionomas and phaeochromacytomas.

Patients who have previously had Lu-177 octreotate are not eligible. Patients may have had any other treatment including chemotherapy, radiotherapy or SSTR analogues.

Costs of all tests, treatment and follow up is covered by Ipsen. The study is open to all patients – public or private.

If you would like further information on the trial or would like to refer a patient for screening assessment please contact us via email: or phone: +61 8 9091 1081.

New Research Hub to Expand Biomedical Imaging Boundaries

Theranostics Australia, in collaboration with other respected industry partners, will work with PhD students and early career researchers on innovative projects at an $8.5m state-of-the-art research hub to be established at The University of Queensland (UQ).

The centre will provide firsthand training to the next generation of scientists, who will expand the boundaries of biomedical imaging to improve healthcare.

The Industrial Transformation Training Centre for Innovation in Biomedical Imaging Technology (CIBIT) will prepare new scientists to work in industry and develop ‘smart’ biotechnology and biomedical imaging techniques.

The UQ Centre for Advanced Imaging (CAI) Director, Professor David Reutens, said the $8.5m research will be funded by a $4.7m Australian Research Council (ARC) grant and $3.8m in cash and in-kind contributions from industry partners.

“It will play a leading role in the future of biomedical imaging,” he said.

“Biomedical imaging has been one of the most important advances in the history of medicine.

“It allows medical professionals to determine the location, nature and extent of disease with high accuracy and sensitivity, and has become an integral part of modern health care.

“This new centre will train industry-ready scientists to lead research into faster, more accurate and more cost-effective diagnostic imaging.”

The centre’s industry driven research will work to overcome barriers in the development and application of novel diagnostics, therapeutics and theranostics for important diseases like cancer.

Sixteen PhD students and five early career researchers will work on projects with industry partners.

The centre will involve researchers from across UQ, including the Centre for Advanced Imaging (CAI), UQ Business School (UQBS), the Australian Institute for Bioengineering and Nanotechnology (AIBN), the UQ Diamantina Institute (UQDI) and the School of Mathematics and Physics (UQSMP).

Industry partners include Siemens Healthcare Pty Ltd, Clarity Pharmaceuticals Pty Ltd, Minomic International Ltd, Inter-K Peptide Therapeutics Ltd, Theranostics Australia Pty Ltd, Beijing Genomics Institute, Brisbane Veterinary Specialists Centre, Uniting Care Medical Imaging, and Red Radiology Pty Ltd.

The centre builds upon previous investments in CAI and the National Imaging Facility (NIF) from the Queensland Government and the Commonwealth Government’s contributions to the NIF through the National Collaborative Research Infrastructure Strategy (NCRIS) and the Education Investment Fund (EIF).

Original Media Release by the University of Queensland: